Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.65 USD
+0.04 (6.72%)
Updated May 17, 2024 04:00 PM ET
After-Market: $0.65 0.00 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGMO 0.65 +0.04(6.72%)
Will SGMO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
Other News for SGMO
Commit To Purchase Sangamo Therapeutics At $0.50, Earn 59.8% Annualized Using Options
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
Buy Rating Affirmed for Sangamo Biosciences on Promising CNS-targeting Capsid and MINT Platform Advancements
Sangamo Biosciences: A Strong Buy on Preclinical Progress and Strategic Partnerships
Sangamo Biosciences: Navigating Biopharma Risks Beyond the Minefield